Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
MtUgdHyNFY4yz9Vj
Listen
